Table 3.
Correlations between percentage change from baseline in UUI episodes and changes in PPBC and KHQ domain scores in subjects treated with TER or placebo
| Placebo | TER | |||
| r | P Value | r | P Value | |
| PPBC | 0.32 | <0.0001 | 0.35 | <0.0001 |
| KHQ domain | ||||
| General Health Perceptions | 0.11 | 0.0252 | 0.09 | 0.0687 |
| Incontinence Impact | 0.27 | <0.0001 | 0.32 | <0.0001 |
| Role Limitations | 0.30 | <0.0001 | 0.16 | 0.0008 |
| Physical Limitations | 0.25 | <0.0001 | 0.23 | 0.0001 |
| Social Limitations | 0.13 | 0.0078 | 0.16 | 0.0011 |
| Personal Relationships | 0.12 | 0.0436 | 0.11 | 0.0773 |
| Emotions | 0.14 | 0.0041 | 0.25 | <0.0001 |
| Sleep/Energy | 0.24 | <0.0001 | 0.19 | 0.0001 |
| Severity/Coping | 0.34 | <0.0001 | 0.30 | <0.0001 |
| Symptom Severity | 0.33 | <0.0001 | 0.32 | <0.0001 |
KHQ = King's Health Questionnaire; PPBC = Patient Perception of Bladder Condition; TER = tolterodine extended release; UUI = urgency urinary incontinence.